Annexon posts Q3 2026 results, flags tanruprubart BLA and ARCHER II readout timingNov 9Quarterly updateAnnexon, Inc.vonaprument
Annexon registers Phase 3 extension study of vonaprument for geographic atrophySep 8Trial updateAnnexon, Inc.vonaprument
Annexon posts results for completed Phase 2a ANX005 study in Huntington's diseaseAug 25Trial updateAnnexon, Inc.ANX005
Annexon reports Q2 2026 results, sets tanruprubart BLA for fourth quarterAug 12Quarterly updateAnnexon, Inc.
Annexon adds retinal surgeon Mark Blumenkranz to board as Muneer Satter departsAug 10PeopleAnnexon, Inc.
Annexon reports early data from first 10 GBS FORWARD study patientsAug 6Regulatory decisionAnnexon, Inc.
Annexon posts results for ANX005 Phase 2 wAIHA study, completed with 7 participantsJun 30Trial updateAnnexon, Inc.ANX005